Terms: = Lung cancer AND CCND3, P30281, 896, ENSG00000112576 AND Treatment
46 results:
1. Influence of
Naqash AR; Floudas CS; Aber E; Maoz A; Nassar AH; Adib E; Choucair K; Xiu J; Baca Y; Ricciuti B; Alessi JV; Awad MM; Kim C; Judd J; Raez LE; Lopes G; Nieva JJ; Borghaei H; Takebe N; Ma PC; Halmos B; Kwiatkowski DJ; Liu SV; Mamdani H
JCO Precis Oncol; 2024 Feb; 8():e2300371. PubMed ID: 38330261
[TBL] [Abstract] [Full Text] [Related]
2. A novel sub-regional radiomics model to predict immunotherapy response in non-small cell lung carcinoma.
Peng J; Zou D; Zhang X; Ma H; Han L; Yao B
J Transl Med; 2024 Jan; 22(1):87. PubMed ID: 38254087
[TBL] [Abstract] [Full Text] [Related]
3. Multi-classification model incorporating radiomics and clinic-radiological features for predicting invasiveness and differentiation of pulmonary adenocarcinoma nodules.
Sun H; Zhang C; Ouyang A; Dai Z; Song P; Yao J
Biomed Eng Online; 2023 Nov; 22(1):112. PubMed ID: 38037082
[TBL] [Abstract] [Full Text] [Related]
4. Patterns of care for people with small cell lung cancer in Victoria, 2011-19: a retrospective, population-based registry data study.
Huang J; Faisal W; Brand M; Smith S; Alexander M; Briggs L; Conron M; Duffy M; John T; Langton D; Lesage J; MacManus M; Mitchell P; Olesen I; Parente P; Philip J; Samuel E; Torres J; Underhill CR; Zalcberg JR; Harden S; Stirling R
Med J Aust; 2023 Aug; 219(3):120-126. PubMed ID: 37365486
[TBL] [Abstract] [Full Text] [Related]
5. Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency treatment Consortium.
Thakar MS; Logan BR; Puck JM; Dunn EA; Buckley RH; Cowan MJ; O'Reilly RJ; Kapoor N; Satter LF; Pai SY; Heimall J; Chandra S; Ebens CL; Chellapandian D; Williams O; Burroughs LM; Saldana BD; Rayes A; Madden LM; Chandrakasan S; Bednarski JJ; DeSantes KB; Cuvelier GDE; Teira P; Gillio AP; Eissa H; Knutsen AP; Goldman FD; Aquino VM; Shereck EB; Moore TB; Caywood EH; Lugt MTV; Rozmus J; Broglie L; Yu LC; Shah AJ; Andolina JR; Liu X; Parrott RE; Dara J; Prockop S; Martinez CA; Kapadia M; Jyonouchi SC; Sullivan KE; Bleesing JJ; Chaudhury S; Petrovic A; Keller MD; Quigg TC; Parikh S; Shenoy S; Seroogy C; Rubin T; Decaluwe H; Routes JM; Torgerson TR; Leiding JW; Pulsipher MA; Kohn DB; Griffith LM; Haddad E; Dvorak CC; Notarangelo LD
Lancet; 2023 Jul; 402(10396):129-140. PubMed ID: 37352885
[TBL] [Abstract] [Full Text] [Related]
6. CT-based radiomics models may predict the early efficacy of microwave ablation in malignant lung tumors.
Zhu F; Yang C; Xia Y; Wang J; Zou J; Zhao L; Zhao Z
Cancer Imaging; 2023 Jun; 23(1):60. PubMed ID: 37308918
[TBL] [Abstract] [Full Text] [Related]
7. Budget impact analysis of comprehensive genomic profiling for untreated advanced or recurrent solid cancers in Japan.
Tang W; Hanada K; Motoo Y; Sakamaki H; Oda T; Furuta K; Abutani H; Ito S; Tsutani K
J Med Econ; 2023; 26(1):614-626. PubMed ID: 37073487
[TBL] [Abstract] [Full Text] [Related]
8. A deep belief network-based clinical decision system for patients with osteosarcoma.
Li W; Dong Y; Liu W; Tang Z; Sun C; Lowe S; Chen S; Bentley R; Zhou Q; Xu C; Li W; Wang B; Wang H; Dong S; Hu Z; Liu Q; Cai X; Feng X; Zhao W; Yin C
Front Immunol; 2022; 13():1003347. PubMed ID: 36466868
[TBL] [Abstract] [Full Text] [Related]
9. The Effect of immunotherapy on oligometastatic non-small cell lung cancer patients by sites of metastasis.
Ma JC; Zhang JX; Wang F; Yu J; Chen D
Front Immunol; 2022; 13():1039157. PubMed ID: 36451822
[TBL] [Abstract] [Full Text] [Related]
10. Comparison of aprepitant versus desloratadine for EGFR-TKI-induced pruritus: A randomized phase 2 clinical trial.
Zhou T; Zhang Y; Ma Y; Ma W; Wu X; Huang L; Feng W; Zhou H; Liu J; Zhao H; Zhang L; Yang Y; Huang Y
Cancer; 2022 Nov; 128(22):3969-3976. PubMed ID: 36197287
[TBL] [Abstract] [Full Text] [Related]
11. High-Resolution Profiling of lung Adenocarcinoma Identifies Expression Subtypes with Specific Biomarkers and Clinically Relevant Vulnerabilities.
Roh W; Geffen Y; Cha H; Miller M; Anand S; Kim J; Heiman DI; Gainor JF; Laird PW; Cherniack AD; Ock CY; Lee SH; Getz G;
Cancer Res; 2022 Nov; 82(21):3917-3931. PubMed ID: 36040373
[TBL] [Abstract] [Full Text] [Related]
12. Access to Care Metrics in Stage I lung cancer: Improved Access Is Associated With Improved Survival.
Heiden BT; Eaton DB; Chang SH; Yan Y; Schoen MW; Patel MR; Kreisel D; Nava RG; Samson P; Meyers BF; Kozower BD; Puri V
Ann Thorac Surg; 2022 Nov; 114(5):1810-1815. PubMed ID: 35724700
[TBL] [Abstract] [Full Text] [Related]
13. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
14. BAP18 induces growth of non-small-cell lung carcinoma through upregulating transcriptional level of CCND1/2.
Wei SJ; Li J; Wang JY; Zhang LX; Zhang HB; Du DJ; Li QX
Eur Rev Med Pharmacol Sci; 2022 May; 26(9):3074-3082. PubMed ID: 35587057
[TBL] [Abstract] [Full Text] [Related]
15. Development and Validation of a Radiomics Nomogram Using Computed Tomography for Differentiating Immune Checkpoint Inhibitor-Related Pneumonitis From Radiation Pneumonitis for Patients With Non-Small Cell lung cancer.
Qiu Q; Xing L; Wang Y; Feng A; Wen Q
Front Immunol; 2022; 13():870842. PubMed ID: 35558076
[TBL] [Abstract] [Full Text] [Related]
16. Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer.
Sitthideatphaiboon P; Teerapakpinyo C; Korphaisarn K; Leelayuwatanakul N; Pornpatrananrak N; Poungvarin N; Chantranuwat P; Shuangshoti S; Aporntewan C; Chintanapakdee W; Sriuranpong V; Vinayanuwattikun C
Sci Rep; 2022 Feb; 12(1):2167. PubMed ID: 35140316
[TBL] [Abstract] [Full Text] [Related]
17. Differentiation between immune checkpoint inhibitor-related and radiation pneumonitis in lung cancer by CT radiomics and machine learning.
Cheng J; Pan Y; Huang W; Huang K; Cui Y; Hong W; Wang L; Ni D; Tan P
Med Phys; 2022 Mar; 49(3):1547-1558. PubMed ID: 35026041
[TBL] [Abstract] [Full Text] [Related]
18. Alterations of the Human lung and Gut Microbiomes in Non-Small Cell lung Carcinomas and Distant Metastasis.
Lu H; Gao NL; Tong F; Wang J; Li H; Zhang R; Ma H; Yang N; Zhang Y; Wang Y; Liang Z; Zeng H; Chen WH; Dong X
Microbiol Spectr; 2021 Dec; 9(3):e0080221. PubMed ID: 34787462
[TBL] [Abstract] [Full Text] [Related]
19. Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50.
Wang L; Peng Y; Zeng X; Peng L; Li S; Qin S; Wan X; Tan C
Adv Ther; 2021 Aug; 38(8):4354-4365. PubMed ID: 34241780
[TBL] [Abstract] [Full Text] [Related]
20. NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.
Sánchez-Herrero E; Serna-Blasco R; Ivanchuk V; García-Campelo R; Dómine Gómez M; Sánchez JM; Massutí B; Reguart N; Camps C; Sanz-Moreno S; Calabuig-Fariñas S; Jantus-Lewintre E; Arnal M; Fernández-Orth D; Calvo V; González-Rumayor V; Provencio M; Romero A
Mol Oncol; 2021 Sep; 15(9):2363-2376. PubMed ID: 34058070
[TBL] [Abstract] [Full Text] [Related]
[Next]
